One in three individuals receiving CHD secondary prevention care has hypertriglyceridaemia (HTG), despite the fact that 85% use lipid-modifying therapies, mainly statins. This was one of the key findings from the INTERASPIRE study of 4,069 CHD secondary prevention patients managed in 13 countries across six WHO regions.
